BCMA72-80 CAS Nr .: 2293841-58-2

Xa kev nug
BCMA72-80 CAS Nr .: 2293841-58-2
Paub meej
CAS: 2293841-58-2 Nr
Sequence: YLMFLLRKI
Peb kuj muab cov lus qhia tshwj xeeb los ntawm crude mus rau 98% purity, thov hu rau peb kom paub meej!

Cov ntaub ntawv ntsig txog
COA/MS/HPLC Report
Peptide Dissolution thiab Storage Guide
Kev faib tawm yam khoom
Epitope Peptides
Share to
Hauj lwm lawm

Shanghai Sunite Biotechnology Co., Ltd. yog ib qho ntawm cov ua lag luam thiab cov muag khoom ntawm bcma72-80 cas 2293841-58-2 hauv Suav teb, kuj txhawb kev pabcuam kev cai. Txais tos rau kev lag luam wholesale bulk zoo bcma72-80 cas 2293841-58-2 los ntawm peb lub hoobkas. Tiv tauj peb kom paub meej ntxiv.

 

Khoom npe CAS Nr .: 2293841-58-2; BCMA72-80
Ib ntus YLMFLLRKI
Peb tsab ntawv ib ntus Tyr-Leu-Met-Phe-Leu-Leu-Arg-Lys-Ile
Peptide purity (HPLC, %) 95%/98%
Cov mis mos molecular C59H97N13O11S
Molecular Luj (Da) 1196.55

 

Product Basic Information Table

 

Khoom Lub Npe Lus Askiv

Product Abbreviation / Alias

Function Tags (comma-sib cais)

Amino Acid Tag Nrho Lub Npe Sequence

Molecular Formula

Qhov hnyav Molecular (Da)

Qhov Nruab Nrab Molecular Luj (Da)

Terminal Hloov kho - N-terminus

Terminal Hloov kho - C-terminus

Qhov ntev (aa)

PIB (72-80)

#BCMA72-80 #BCMA qog antigen epitope; #CAR-T phiaj peptide; #MHC chav kawm kuv txwv CTL epitope

Tumor immunodominant epitope, BCMA targeted therapy, multiple myeloma, CD8+ T cell activation, in vitro CAR-T screening, anti-mob tshuaj tiv thaiv kab mob

Leucine-Arginine-Glutamine-Tryptophan-Isoleucine-Aspartic acid-Proline-Glutamine-Valine

C₅₃H₈₄N₂₀O₁₃

1244.647

1245.36

Tsis hloov

Dawb carboxyl pawg

9

 

Physicochemical Solubility & Cia Parameters

 

Khoom Code

Qhov tshwm sim

Pom zoo Dissolution Protocol (los ntawm hnyav)

Solubility Reference

Tsis pom zoo Solvents

Ntev - Lub Sij Hawm Cia Cov Cai

Luv luv -Lub Sijhawm Cia Cia

Kua Stability

Khoom hmoov ruaj khov

Muaj feem xyuam pH Range

PEB-BCMA01

Dawb lyophilized hmoov

Dilute acetic acid, dej ultrapure; Tsawg solubility nyob rau hauv nruab nrab cov dej ntshiab, ntxiv glacial acetic acid los txhim kho solubility

Ntau dua lossis sib npaug li 10mg / mL hauv 0.1% aqueous acetic acid

Tsis muaj dej ntshiab, alkane organic solvents

-20 degree, kaw kom deb ntawm lub teeb, aliquoted, tsis txhob rov khov-thaw

2-8 degree, siv hauv 1 lub hlis; npaj tshiab ua ntej kev sim

Ruaj khov rau 24 teev ntawm 4 degree

3 xyoos ntawm -20 degree, 2 xyoos ntawm 4 degree

3.0-7.0

 

Functional Description

 

Khoom Code

Frontend Short Summary (rau cov npe tshawb nrhiav)

Cov lus piav qhia txog kev ua haujlwm lom neeg lom neeg

Cov Cheeb Tsam Tshawb Fawb (comma- cais)

Hom phiaj / Receptor

PEB-BCMA01

BCMA (72-80) yog myeloma- tshwj xeeb MHC-Kuv qog epitope rau hauv vitro functional validation ntawm BCMA CAR-T thiab anti-tumor tiv thaiv kev tshawb fawb

BCMA (72-80) yog ib qho immunodominant nonapeptide epitope muab los ntawm extracellular domain ntawm B cell maturation antigen, uas ruaj khov khi tib neeg MHC class I molecules thiab tshwj xeeb activates BCMA-reactive CD8⁺ cytotoxic T cells. BCMA yog qhov tshwj xeeb thiab tshwj xeeb tshaj tawm rau ntau lub hlwb qog nqaij hlav myeloma, ua raws li lub hom phiaj tseem ceeb rau CAR-T thiab cov tshuaj tiv thaiv kab mob- tshuaj conjugates. Cov peptide no ua haujlwm raws li tus qauv antigen substrate rau ELISPOT, T cell tua kev soj ntsuam thiab ntws cytometry antigen stimulation. Kev siv dav dav hauv hematological malignancy anti- qog tiv thaiv kab mob, CAR-T kev ntsuas kev ua tau zoo, kev tsim tshuaj tiv thaiv kab mob neoantigen thiab hauv vitro tshuaj ntsuam xyuas ntawm lub cev tiv thaiv kab mob, tsim rau cov qog immunology thiab hematologic oncology kev tshawb fawb tshuaj

Hematological qog immunology, ntau yam myeloma, BCMA targeted immunotherapy, MHC-I antigen presentation, CTL activation, in vitro CAR-T functional validation

MHC chav kawm I molecules, CD8⁺ T cell receptor, BCMA- tshwj xeeb TCR / antibody

 

Cov Ntaub Ntawv Tswj Xyuas Zoo

 

Khoom Code

Purity Detection Method

Molecular Weight Verification Method

Kev Tswj Xyuas Qhov Ntsuas

Impurity Control Standards

PEB-BCMA01

Rov qab-theem HPLC

ESI-MS Mass Spectrometry

Purity, dej ntsiab lus, acetate ntsev, hnyav hlau

Ib qho impurity Tsawg dua lossis sib npaug li 2%, tag nrho impurities Tsawg dua lossis sib npaug li 5%

 

SKU Specifications & Inventory Table

 

SKU Unique Code

Yam khoom Code

HPLC Purity

Ntim Specification

Lub Sijhawm Ua Haujlwm Ntau Lawm

Customizable

Optional Custom Modifications

Cov ntaub ntawv suav nrog

PEB-BCMA01-98-1

PEB-BCMA01

Ntau dua lossis sib npaug li 98%

1mg ib

3-7 hnub ua haujlwm

Yog lawm

Acetylation, amidation, fluorescent labeling, biotin labeling

CoA, HPLC chromatogram, MS mass spectrum

PEB-BCMA01-98-5

PEB-BCMA01

Ntau dua lossis sib npaug li 98%

5mg ib

3-7 hnub ua haujlwm

Yog lawm

Acetylation, amidation, fluorescent labeling, biotin labeling

CoA, HPLC chromatogram, MS mass spectrum

PEB-BCMA01-95-1

PEB-BCMA01

Ntau dua lossis sib npaug li 95%

1mg ib

3-7 hnub ua haujlwm

Yog lawm

Acetylation, amidation, fluorescent labeling, biotin labeling

CoA, HPLC chromatogram, MS mass spectrum

Cim npe nrov: bcma72-80 cas 2293841-58-2, Tuam Tshoj bcma72-80 cas 2293841-58-2 manufacturers, lwm tus, Hoobkas

Xa kev nug